Concentration dependent plasma protein binding of salicylate in rheumatoid patients.
Acetylsalicylic acid in daily doses from 3 to 6g was prescribed to 8 patients with rheumatoid arthritis. Various assessments of clinical effect, as well as steady-state plasma concentrations and degree of plasma protein binding, were determined at each dose. The unbound fraction of salicylate increased with the dose, resulting in very high free concentrations of drug in some patients. No statistically significant relationship between total or unbound plasma concentration and the measurements of clinical efficacy were obtained. The marked increase with the dose in unbound salicylate concentration is interpreted as the result of the saturable elimination known to occur for this drug.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001241:Aspirin / Q000378:metabolism / Q000627:therapeutic use; D001798:Blood Proteins / Q000378:metabolism*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D012459:Salicylates / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D013997:Time Factors
D001798:Blood Proteins; D012459:Salicylates; D001241:Aspirin